Furthermore, GLP-1 analogs are associated with improved pulmonary outcomes, including a lower risk of pneumonia, reduced oxygen dependence, and decreased all-cause mortality in COPD patients receiving single-inhaler triple therapy (SITT) [296]. The gene discussed is GLP1R; the disease is susceptibility to pneumonia measurement.